Previous 10 | Next 10 |
Harrow Health, Inc. (Nasdaq: HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable, today announced that it will release its financial results for th...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: iQoncept / Shutterstock.com Given the way the market’s acting today, now may not seem like the best time to pursue “moonshot” plays. Rising interest rates keep putting pressure on formerly h...
Harrow Health (NASDAQ:HROW) has filed for a $300M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for general corporate purposes and working capital requirements. The offering can i...
Harrow began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Growth is robust, with Q1 2022 revenue up 43% YOY. Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow unde...
Harrow Health’s (HROW) Q1 2022 Earnings Conference Call May 05, 2022 04:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive Officer and Chairman of the Board Andrew Boll - Chief Financial Officer Conference Call Parti...
The following slide deck was published by Harrow Health, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Harrow Health, Inc. 2022 Q1 - Results - Earnings Call Presentation
Harrow Health press release (NASDAQ:HROW): Q1 Non-GAAP EPS of $0.03 beats by $0.07. Revenue of $22.12M (+43.3% Y/Y) beats by $2.64M. For further details see: Harrow Health Non-GAAP EPS of $0.03 beats by $0.07, revenue of $22.12M beats by $2.64M
Seventh Consecutive Quarter of Record Results Highlights for First Quarter 2022: Record revenues of $22.1 million, up 43% over $15.4 million for the prior-year quarter Record gross profit of $16.2 million, up 38% over $11.7 million for the prior-year quarter Record...
Bioavailability of MELT-210 Compares Favorably to Reference Drug Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced top-line results of its phase 1 pharmacokinetics (PK) study...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...